In what is being considered a major advancement in the field of stem cell research, researchers have used a cloning method to successfully reprogram human skins cells into embryonic stem cells.
It's a great time to helm a large biotech company, generally. Big biotech players overall posted major growth last year, and their CEOs got richer in the process. Most got fat raises while others saw their bundles of pay pale in comparison to 2011 figures.
We surveyed the total compensation packages of the 10 largest biotech companies based on market capitalization as of early May, sleuthing mostly proxy statements for the financial details on pay for some of the most powerful people in the industry.
Last year the chief executives of the 10 companies garnered total compensation of $115.93 million, a 16.57% jump from the $99.45 million in total pay the execs got in 2011.
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field.
The gross research budgets for these companies hit $70.37 billion last year, down ever so slightly from $70.38 billion the year before, when viewed at constant exchange rates. But while most companies carefully stayed on an unchanged budget track--Novartis ($NVS), Merck ($MRK), J&J ($JNJ), GlaxoSmithKline ($GSK), Sanofi ($SNY), Eli Lilly ($LLY), AstraZeneca ($AZN) and Abbott ($ABT)--Pfizer ($PFE) registered the big drop in spending that had long ago been forecast. Roche ($RHHBY), meanwhile, saw its numbers jump in the face of some big, one-time restructuring costs. And Abbott ($ABT) is making an appearance for the last time as AbbVie ($ABBV) has now spun out to forge its own unique path in the biopharma business. Read the report >>
POPULAR COMMENT THREADS
U.K. researchers may have identified a catalytic trigger for the onset of Alzheimer's disease--a finding that could help doctors diagnose the disease earlier and potentially pave the way for a new class of drugs desperately needed to help treat the debilitating disease.
Danish pharmaceutical group Lundbeck on Wednesday reported that its investigational depression drug vortioxetine improved a number of cognitive functions in preclinical animal models.
Alnylam Pharmaceuticals has reported upbeat preclinical findings in a proof-of-concept study for its RNAi therapeutic program to treat porphyria, including acute intermittent porphyria, a rare genetic metabolic disorder caused by an enzyme deficiency.
An enzyme inhibitor that helps repair DNA damage may provide a new way to boost the effectiveness of radiation therapy for a lethal type of brain cancer.
A new drug developed by researchers at Georgetown University Medical Center may be able to stop the progression of a rare bone cancer that affects children and adolescents.
MIT researchers may have discovered a key protein involved in cell death--one that could help kill remaining cancer cells after chemotherapy.
From Our Sister Sites
A slew of potential bidders will likely bid for Panasonic's healthcare unit, boosting the Japanese consumer electronics giant's chances of raising as much as $1 billion to grow its med tech offerings.
Roche won the FDA's blessing to market a hemoglobin-based diabetes diagnostic, the latest advance in testing for the disease and the first assay of its kind approved in the U.S.